Download or read book Targeted Therapy of Acute Myeloid Leukemia written by Michael Andreeff and published by Springer. This book was released on 2014-11-20 with total page 805 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides an unprecedented overview of "Targeted Therapies" for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make "leukemia history" in the near future.
Download or read book Target Therapy in Acute Myeloid Leukemia written by Vasko Graklanov and published by . This book was released on 2018 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Acute myeloid leukemia (AML) is the most common form of acute leukemia in elderly patients. Over the past four decades the basic therapeutic armamentarium was the standard cytotoxic treatment. The new insights in understanding the pathogenesis of AML was the momentum that revolutionized the treatment landscape in AML. The last five years unprecedented growth has been seen in the number of target therapy drugs for the treatment of AML. These new drugs did not just have a clinical benefit as single agents but also have improved AML patient outcomes if combined with conventional cytotoxic therapy. Here, we review recent advances in target-based therapy for patients with AML focusing on their mechanism of action and the results from already published clinical trials.
Download or read book Allogeneic Stem Cell Transplantation written by Hillard M. Lazarus and published by Springer Science & Business Media. This book was released on 2010-03-02 with total page 885 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.
Download or read book Molecularly Targeted Therapy for Childhood Cancer written by Peter J. Houghton and published by Springer Science & Business Media. This book was released on 2010-09-10 with total page 548 pages. Available in PDF, EPUB and Kindle. Book excerpt: Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular ‘drivers’ can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.
Download or read book Acute Myelogenous Leukemia written by Lalitha Nagarajan and published by Springer Science & Business Media. This book was released on 2010-03-20 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
Download or read book Fast Facts Acute Myeloid Leukemia written by William Blum and published by Karger Medical and Scientific Publishers. This book was released on 2018-05-14 with total page 90 pages. Available in PDF, EPUB and Kindle. Book excerpt: This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: • Epidemiology, pathophysiology and etiology • Diagnosis • Treatment • Supportive care • Prognosis and monitoring • Emerging treatments • Useful resources
Download or read book New Therapies for Acute Myeloid Leukaemia written by Paul Faduola and published by iMedPub. This book was released on 2015-04-28 with total page 118 pages. Available in PDF, EPUB and Kindle. Book excerpt: Stem cell transfusion have undeniable benefits for patients with Acute Myeloid Leukemia (AML) especially for augmenting the mostly suppressed normal precursor stem cell necessary for fighting infections. While many patients use own stem cells, other patients that might benefit from this treatment are unable to use own stem cells and may lack Human Leucocyte Antigen (HLA) identical donor because of HLA polymorphism. Stem cells collected from the bone marrow , umbilical cord blood and peripheral blood stem cells may be from own or HLA partially mismatched unrelated or related donors. The data obtained show that hematologic recovery is highest in peripheral blood and lower in cord blood than in bone marrow, graft versus host disease is higher in peripheral blood than in bone marrow and lowest in cord blood, incidence of relapse and survival were comparable across sources , mortality is higher in cord blood than in peripheral blood and bone marrow and is mostly as a result of infection due to poor engraftment .This comparison is aimed at improving the quality of decision taking on source of stem cells for transfusion in cases of AML as it compares cord blood, peripheral blood and bone marrow in a single study .
Download or read book Innovative Medicine written by Kazuwa Nakao and published by Springer. This book was released on 2015-10-13 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is devoted to innovative medicine, comprising the proceedings of the Uehara Memorial Foundation Symposium 2014. It remains extremely rare for the findings of basic research to be developed into clinical applications, and it takes a long time for the process to be achieved. The task of advancing the development of basic research into clinical reality lies with translational science, yet the field seems to struggle to find a way to move forward. To create innovative medical technology, many steps need to be taken: development and analysis of optimal animal models of human diseases, elucidation of genomic and epidemiological data, and establishment of “proof of concept”. There is also considerable demand for progress in drug research, new surgical procedures, and new clinical devices and equipment. While the original research target may be rare diseases, it is also important to apply those findings more broadly to common diseases. The book covers a wide range of topics and is organized into three complementary parts. The first part is basic research for innovative medicine, the second is translational research for innovative medicine, and the third is new technology for innovative medicine. This book helps to understand innovative medicine and to make progress in its realization.
Download or read book Leukemias written by Stefan Faderl and published by John Wiley & Sons. This book was released on 2011-09-14 with total page 460 pages. Available in PDF, EPUB and Kindle. Book excerpt: Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include: Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents Leukemias: Principles and Practice of Therapy Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area
Download or read book Chemotherapy for Leukemia written by Takanori Ueda and published by Springer. This book was released on 2017-04-17 with total page 354 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.
Download or read book Management of Hematologic Malignancies written by Susan O'Brien and published by Cambridge University Press. This book was released on 2010-11-18 with total page 527 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology.
Download or read book Targeted Therapy in Translational Cancer Research written by Apostolia-Maria Tsimberidou and published by John Wiley & Sons. This book was released on 2015-12-21 with total page 396 pages. Available in PDF, EPUB and Kindle. Book excerpt: Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities
Download or read book Acute Promyelitic Leukemia written by Pier Paolo Pandolfi and published by Springer Science & Business Media. This book was released on 2007-02-02 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt: Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.
Download or read book Drug Resistance in Leukemia written by Gert-Jan L. Kaspers and published by CRC Press. This book was released on 1993-01-01 with total page 458 pages. Available in PDF, EPUB and Kindle. Book excerpt: The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols.
Download or read book The EBMT EHA CAR T Cell Handbook written by Nicolaus Kröger and published by Springer Nature. This book was released on 2022-02-07 with total page 221 pages. Available in PDF, EPUB and Kindle. Book excerpt: This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.
Download or read book New Agents for the Treatment of Acute Lymphoblastic Leukemia written by Vaskar Saha and published by Springer Science & Business Media. This book was released on 2011-05-07 with total page 349 pages. Available in PDF, EPUB and Kindle. Book excerpt: The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of pre-invasive disease and what the public health implications might be for wide-scale screening programmes. In the western world we already have experience of screening for cervical, breast, prostate and more recently colon cancer. As well as their potential benefits these programmes have financial and psychosocial implications which need to be carefully weighed. This is especially true since many pre-invasive lesions will not progress to cancer in a individual’s lifetime. In addition, there are questions concerning whether screening reduces the cancer burden or in fact distorts the survival figures through lead-time bias. Secondly, at the level of epidemiology and molecular pathogenesis there are important questions regarding the aetiology of pre-invasive lesions; an understanding of which might lead to possible chemopreventive strategies. For example, it would be helpful to know the extent to which the likelihood of developing a pre-invasive lesion is influenced by lifestyle or genetic factors and how these factors influence the risk of progression to invasive disease. At the molecular level we need to understand the pathways and molecular mechanisms, both genetic and epigenetic, by which cells achieve the capacity to invade. Thirdly, in order make clinical progress we need biomarkers to identify and risk stratify individuals with pre-invasive lesions. These biomarkers might be applied to the serum as in Prostate Specific Antigen in prostate cancer or be applied to tissue samples, such as oestrogen receptor status in breast cancer. In order to utilize biomarkers in the context of a screening programme there are issue around the invasiveness of the test as well as its positive and negative predictive value. With advances in molecular imaging there is now the exciting possibility of incorporating a molecular tag to a non-invasive imaging modality. Fourthly, in order to justify screening early detection must be coupled to a treatment strategy. If the chemopreventive agent is very well tolerated, then as well as targeting high risk groups, one might consider treatment at the population level. Aspirin is one such drug which has been extensively assessed in the context of colon cancer chemoprevention trials. Trials of aspirin chemoprevention are now being applied to other cancers such as oesophageal adenocarcinoma and since many individuals take aspirin for .chemoprevention of cardiovascular disease the cancer incidence can be ascertained in these populations. In order to understand the more general issues raised from the discussions above it is useful to consider disease specific examples. Our understanding of pre-invasive disease varies according to the organ site and there are lessons to be learned from these experiences. For example, there is now the prospect of a vaccine for cervical cancer with important questions about how this might be applied to the high incidence areas of the developing world. On the other hand, ductal carcinoma in situ is currently treated by mastectomy which is more radical than the treatment received by many women with invasive disease. Oesophageal adenocarcinoma, which is my own area of expertise is interesting because of the rapid rise in incidence in the western world and the clinically accessible pre-invasive lesion called Barrett’s oesophagus. However, most cases of Barrett’s oesophagus remain undiagnosed and it is not yet clear how to effectively diagnose, monitor and treat this condition without recourse to mass endoscopy with substantial cost implications. In conclusion, in an era in which preventive medicine is a major concern for consumers, health-policy makers and politicians pre-invasive disease is likely to become a major part of cancer medicine.
Download or read book Acute Myelogenous Leukemia written by Lalitha Nagarajan and published by Springer. This book was released on 2011-11-02 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
